glp-1/gip/glucagon triple agonist New strategies for the treatment of obesity and metabolic dysfunctions GLP-1 for Weight Loss and

In fact, some studies found that semaglutide (GLP-1 RA) medications helped people lose an average of 9%-17% of their body weight in a little over a year

Unexpected cardiovascular risks of glucagon-like peptide-1 receptor agonist and aspirin co-administration in individuals with obesity, with and without type 2 diabetes: a propensity score matched cohort study

The largest psychiatric safety meta-analysis to date found that GLP-1 medications were not associated with increased risk of serious psychiatric adverse events overall ( Pierret et al., JAMA Psychiatry, 2025 ), and a post-hoc analysis of the major semaglutide weight management trials found no differences in depression, suicidal ideation, or suicidal behavior compared to placebo ( Wadden et al., JAMA Internal Medicine, 2024 )

For many women with PCOS, the underlying insulin resistance is a chronic condition

Our GLP-1 Berberine capsules are made in the USA and safety tested for heavy metal and microbes in a state of the art facility